Integra LifeSciences Holdings Corporation $IART Shares Purchased by UBS Group AG

UBS Group AG lifted its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 211.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 408,969 shares of the life sciences company’s stock after acquiring an additional 277,745 shares during the quarter. UBS Group AG owned 0.53% of Integra LifeSciences worth $5,079,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Osaic Holdings Inc. lifted its holdings in shares of Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Integra LifeSciences by 145.9% in the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock worth $78,000 after acquiring an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after acquiring an additional 6,814 shares during the last quarter. Amundi lifted its holdings in shares of Integra LifeSciences by 17,193.8% in the 2nd quarter. Amundi now owns 11,068 shares of the life sciences company’s stock worth $150,000 after acquiring an additional 11,004 shares during the last quarter. Finally, Inceptionr LLC acquired a new position in shares of Integra LifeSciences in the 3rd quarter worth approximately $164,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

Shares of IART opened at $15.12 on Friday. Integra LifeSciences Holdings Corporation has a fifty-two week low of $8.70 and a fifty-two week high of $16.49. The firm’s 50 day moving average price is $10.99 and its 200 day moving average price is $11.67. The company has a market cap of $1.18 billion, a P/E ratio of -2.34, a PEG ratio of 1.07 and a beta of 1.08. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The firm had revenue of $391.92 million for the quarter, compared to the consensus estimate of $381.81 million. During the same period in the prior year, the firm earned $0.41 EPS. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on IART shares. Citigroup upped their price objective on shares of Integra LifeSciences from $9.00 to $11.00 and gave the stock a “sell” rating in a report on Wednesday, May 6th. Truist Financial decreased their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Wells Fargo & Company upped their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Three equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $12.75.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.